Hubbry Logo
InflammationInflammationMain
Open search
Inflammation
Community hub
Inflammation
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Inflammation
Inflammation
from Wikipedia

Inflammation
An allergic reaction to cefaclor has led to inflammation of the skin on the foot. The cardinal signs of inflammation include: pain, heat, redness, swelling, and loss of function. Some of these indicators can be seen here.
SpecialtyImmunology, rheumatology
SymptomsHeat, pain, redness, swelling
ComplicationsAsthma, pneumonia, autoimmune diseases
DurationAcute: few days
Chronic: up to many months, or years
CausesInfection, physical injury, autoimmune disorder

Inflammation (from Latin: inflammatio) is part of the biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. The five cardinal signs are heat, pain, redness, swelling, and loss of function (Latin calor, dolor, rubor, tumor, and functio laesa).

Description

[edit]

Inflammation is a generic response, and therefore is considered a mechanism of innate immunity, whereas adaptive immunity is specific to each pathogen.[1] It is part of the biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants.[2]

Inflammation is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out damaged cells and tissues, and initiate tissue repair. Too little inflammation could lead to progressive tissue destruction by the harmful stimulus (e.g. bacteria) and compromise the survival of the organism. However inflammation can also have negative effects.[3] Too much inflammation, in the form of chronic inflammation, is associated with various diseases, such as hay fever, periodontal disease, atherosclerosis, and osteoarthritis.

Inflammation can be classified as acute or chronic. Acute inflammation is the initial response of the body to harmful stimuli, and is achieved by the increased movement of plasma and leukocytes (in particular granulocytes) from the blood into the injured tissues. A series of biochemical events propagates and matures the inflammatory response, involving the local vascular system, the immune system, and various cells in the injured tissue. Prolonged inflammation, known as chronic inflammation, leads to a progressive shift in the type of cells present at the site of inflammation, such as mononuclear cells, and involves simultaneous destruction and healing of the tissue.

Inflammation has also been classified as Type 1 and Type 2 based on the type of cytokines and helper T cells (Th1 and Th2) involved.[4]

Meaning

[edit]

The earliest known reference for the term inflammation is around the early 15th century. The word root comes from Old French inflammation around the 14th century, which then comes from Latin inflammatio or inflammationem. Literally, the term relates to the word "flame", as the property of being "set on fire" or "to burn".[5]

The term inflammation is not a synonym for infection. Infection describes the interaction between the action of microbial invasion and the reaction of the body's inflammatory response—the two components are considered together in discussion of infection, and the word is used to imply a microbial invasive cause for the observed inflammatory reaction. Inflammation, on the other hand, describes just the body's immunovascular response, regardless of cause. But, because the two are often correlated, words ending in the suffix -itis (which means inflammation) are sometimes informally described as referring to infection: for example, the word urethritis strictly means only "urethral inflammation", but clinical health care providers usually discuss urethritis as a urethral infection because urethral microbial invasion is the most common cause of urethritis. However, the inflammation–infection distinction is crucial in situations in pathology and medical diagnosis that involve inflammation that is not driven by microbial invasion, such as cases of atherosclerosis, trauma, ischemia, and autoimmune diseases (including type III hypersensitivity).

Causes

[edit]
Physical:

Biological:

Chemical:[6]

Psychological:

Types

[edit]
Comparison between acute and chronic inflammation:
Acute Chronic
Causative agent Bacterial pathogens, injured tissues Persistent acute inflammation due to non-degradable pathogens, viral infection, persistent foreign bodies, or autoimmune reactions
Major cells involved neutrophils (primarily), basophils (inflammatory response), and eosinophils (response to helminth worms and parasites), mononuclear cells (monocytes, macrophages) Mononuclear cells (monocytes, macrophages, lymphocytes, plasma cells), fibroblasts
Primary mediators Vasoactive amines, eicosanoids IFN-γ and other cytokines, growth factors, reactive oxygen species, hydrolytic enzymes
Onset Immediate Delayed
Duration Few days Up to many months, or years
Outcomes Resolution, abscess formation, chronic inflammation Tissue destruction, fibrosis, necrosis

Acute

[edit]

Acute inflammation is a short-term process, usually appearing within a few minutes or hours and begins to cease upon the removal of the injurious stimulus.[9] It involves a coordinated and systemic mobilization response locally of various immune, endocrine and neurological mediators of acute inflammation. In a normal healthy response, it becomes activated, clears the pathogen and begins a repair process and then ceases.[10]

Acute inflammation occurs immediately upon injury, lasting only a few days.[11] Cytokines and chemokines promote the migration of neutrophils and macrophages to the site of inflammation.[11] Pathogens, allergens, toxins, burns, and frostbite are some of the typical causes of acute inflammation.[11] Toll-like receptors (TLRs) recognize microbial pathogens.[11] Acute inflammation can be a defensive mechanism to protect tissues against injury.[11] Inflammation lasting 2–6 weeks is designated subacute inflammation.[11][12]

Cardinal signs

[edit]
The classic signs and symptoms of acute inflammation:[a]
English Latin
Redness Rubor
Swelling Tumor
Heat Calor
Pain Dolor
Loss of function Functio laesa[b]

Inflammation is characterized by five cardinal signs,[15][16] (the traditional names of which come from Latin):

The first four (classical signs) were described by Celsus (c. 30 BC–38 AD).[18]

Pain is due to the release of chemicals such as bradykinin and histamine that stimulate nerve endings.[15] Acute inflammation of the lung (usually in response to pneumonia) does not cause pain unless the inflammation involves the parietal pleura, which does have pain-sensitive nerve endings.[15] Heat and redness are due to increased blood flow at body core temperature to the inflamed site. Swelling is caused by accumulation of fluid.

Loss of function
[edit]

The fifth sign, loss of function, is believed to have been added later by Galen,[19] Thomas Sydenham[20] or Rudolf Virchow.[9][15][16] Examples of loss of function include pain that inhibits mobility, severe swelling that prevents movement, having a worse sense of smell during a cold, or having difficulty breathing when bronchitis is present.[21][22] Loss of function has multiple causes.[15]

Acute process

[edit]
A flowchart depicting the events of acute inflammation.[23]
Micrograph showing granulation tissue. H&E stain.

The process of acute inflammation is initiated by resident immune cells already present in the involved tissue, mainly resident macrophages, dendritic cells, histiocytes, Kupffer cells and mast cells. These cells possess surface receptors known as pattern recognition receptors (PRRs), which recognize (i.e., bind) two subclasses of molecules: pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). PAMPs are compounds that are associated with various pathogens, but which are distinguishable from host molecules. DAMPs are compounds that are associated with host-related injury and cell damage.

At the onset of an infection, burn, or other injuries, these cells undergo activation (one of the PRRs recognize a PAMP or DAMP) and release inflammatory mediators responsible for the clinical signs of inflammation. Vasodilation and its resulting increased blood flow causes the redness (rubor) and increased heat (calor). Increased permeability of the blood vessels results in an exudation (leakage) of plasma proteins and fluid into the tissue (edema), which manifests itself as swelling (tumor). Some of the released mediators such as bradykinin increase the sensitivity to pain (hyperalgesia, dolor). The mediator molecules also alter the blood vessels to permit the migration of leukocytes, mainly neutrophils and macrophages, to flow out of the blood vessels (extravasation) and into the tissue. The neutrophils migrate along a chemotactic gradient created by the local cells to reach the site of injury.[9] The loss of function (functio laesa) is probably the result of a neurological reflex in response to pain.

In addition to cell-derived mediators, several acellular biochemical cascade systems—consisting of preformed plasma proteins—act in parallel to initiate and propagate the inflammatory response. These include the complement system activated by bacteria and the coagulation and fibrinolysis systems activated by necrosis (e.g., burn, trauma).[9]

Acute inflammation may be regarded as the first line of defense against injury. Acute inflammatory response requires constant stimulation to be sustained. Inflammatory mediators are short-lived and are quickly degraded in the tissue. Hence, acute inflammation begins to cease once the stimulus has been removed.[9]

Chronic

[edit]

Chronic inflammation is inflammation that lasts for months or years.[12] Macrophages, lymphocytes, and plasma cells predominate in chronic inflammation, in contrast to the neutrophils that predominate in acute inflammation.[12] Diabetes, cardiovascular disease, allergies, and chronic obstructive pulmonary disease are examples of diseases mediated by chronic inflammation.[12] Obesity, smoking, stress and insufficient diet are some of the factors that promote chronic inflammation.[12]

Cardinal signs

[edit]

Common signs and symptoms that develop during chronic inflammation are:[12]

  • Body pain, arthralgia, myalgia
  • Chronic fatigue and insomnia
  • Depression, anxiety and mood disorders
  • Gastrointestinal complications such as constipation, diarrhea, and acid reflux
  • Weight gain or loss
  • Frequent infections

Vascular component

[edit]

Vasodilation and increased permeability

[edit]

As defined, acute inflammation is an immunovascular response to inflammatory stimuli, which can include infection or trauma.[24][25] This means acute inflammation can be broadly divided into a vascular phase that occurs first, followed by a cellular phase involving immune cells (more specifically myeloid granulocytes in the acute setting).[24] The vascular component of acute inflammation involves the movement of plasma fluid, containing important proteins such as fibrin and immunoglobulins (antibodies), into inflamed tissue.

Upon contact with PAMPs, tissue macrophages and mastocytes release vasoactive amines such as histamine and serotonin, as well as eicosanoids such as prostaglandin E2 and leukotriene B4 to remodel the local vasculature.[26] Macrophages and endothelial cells release nitric oxide.[27] These mediators vasodilate and permeabilize the blood vessels, which results in the net distribution of blood plasma from the vessel into the tissue space. The increased collection of fluid into the tissue causes it to swell (edema).[26] This exuded tissue fluid contains various antimicrobial mediators from the plasma such as complement, lysozyme, antibodies, which can immediately deal damage to microbes, and opsonise the microbes in preparation for the cellular phase. If the inflammatory stimulus is a lacerating wound, exuded platelets, coagulants, plasmin and kinins can clot the wounded area using vitamin K-dependent mechanisms[28] and provide haemostasis in the first instance. These clotting mediators also provide a structural staging framework at the inflammatory tissue site in the form of a fibrin lattice – as would construction scaffolding at a construction site – for the purpose of aiding phagocytic debridement and wound repair later on. Some of the exuded tissue fluid is also funneled by lymphatics to the regional lymph nodes, flushing bacteria along to start the recognition and attack phase of the adaptive immune system.

Infected ingrown toenail showing the characteristic redness and swelling associated with acute inflammation

Acute inflammation is characterized by marked vascular changes, including vasodilation, increased permeability and increased blood flow, which are induced by the actions of various inflammatory mediators.[26] Vasodilation occurs first at the arteriole level, progressing to the capillary level, and brings about a net increase in the amount of blood present, causing the redness and heat of inflammation. Increased permeability of the vessels results in the movement of plasma into the tissues, with resultant stasis due to the increase in the concentration of the cells within blood – a condition characterized by enlarged vessels packed with cells. Stasis allows leukocytes to marginate (move) along the endothelium, a process critical to their recruitment into the tissues. Normal flowing blood prevents this, as the shearing force along the periphery of the vessels moves cells in the blood into the middle of the vessel.

Plasma cascade systems

[edit]
  • The complement system, when activated, creates a cascade of chemical reactions that promotes opsonization, chemotaxis, and agglutination, and produces the MAC.
  • The kinin system generates proteins capable of sustaining vasodilation and other physical inflammatory effects.
  • The coagulation system or clotting cascade, which forms a protective protein mesh over sites of injury.
  • The fibrinolysis system, which acts in opposition to the coagulation system, to counterbalance clotting and generate several other inflammatory mediators.

Plasma-derived mediators

[edit]

* non-exhaustive list

Name Produced by Description
Bradykinin Kinin system A vasoactive protein that is able to induce vasodilation, increase vascular permeability, cause smooth muscle contraction, and induce pain.
C3 Complement system Cleaves to produce C3a and C3b. C3a stimulates histamine release by mast cells, thereby producing vasodilation. C3b is able to bind to bacterial cell walls and act as an opsonin, which marks the invader as a target for phagocytosis.
C5a Complement system Stimulates histamine release by mast cells, thereby producing vasodilation. It is also able to act as a chemoattractant to direct cells via chemotaxis to the site of inflammation.
Factor XII (Hageman Factor) Liver A protein that circulates inactively, until activated by collagen, platelets, or exposed basement membranes via conformational change. When activated, it in turn is able to activate three plasma systems involved in inflammation: the kinin system, fibrinolysis system, and coagulation system.
Membrane attack complex Complement system A complex of the complement proteins C5b, C6, C7, C8, and multiple units of C9. The combination and activation of this range of complement proteins forms the membrane attack complex, which is able to insert into bacterial cell walls and causes cell lysis with ensuing bacterial death.
Plasmin Fibrinolysis system Able to break down fibrin clots, cleave complement protein C3, and activate Factor XII.
Thrombin Coagulation system Cleaves the soluble plasma protein fibrinogen to produce insoluble fibrin, which aggregates to form a blood clot. Thrombin can also bind to cells via the PAR1 receptor to trigger several other inflammatory responses, such as production of chemokines and nitric oxide.

Cellular component

[edit]

The cellular component involves leukocytes, which normally reside in blood and must move into the inflamed tissue via extravasation to aid in inflammation.[24] Some act as phagocytes, ingesting bacteria, viruses, and cellular debris. Others release enzymatic granules that damage pathogenic invaders. Leukocytes also release inflammatory mediators that develop and maintain the inflammatory response. In general, acute inflammation is mediated by granulocytes, whereas chronic inflammation is mediated by mononuclear cells such as monocytes and lymphocytes.

Leukocyte extravasation

[edit]
Neutrophils migrate from blood vessels to the infected tissue via chemotaxis, where they remove pathogens through phagocytosis and degranulation
Inflammation is a process by which the body's white blood cells and substances they produce protect us from infection with foreign organisms, such as bacteria and viruses. The (phagocytes) white blood cells are a nonspecific immune response, meaning that they attack any foreign bodies. However, in some diseases, like arthritis, the body's defense system the immune system triggers an inflammatory response when there are no foreign invaders to fight off. In these diseases, called autoimmune diseases, the body's normally protective immune system causes damage to its own tissues. The body responds as if normal tissues are infected or somehow abnormal.

Various leukocytes, particularly neutrophils, are critically involved in the initiation and maintenance of inflammation. These cells must be able to move to the site of injury from their usual location in the blood, therefore mechanisms exist to recruit and direct leukocytes to the appropriate place. The process of leukocyte movement from the blood to the tissues through the blood vessels is known as extravasation and can be broadly divided up into a number of steps:

  1. Leukocyte margination and endothelial adhesion: The white blood cells within the vessels which are generally centrally located move peripherally towards the walls of the vessels.[29] Activated macrophages in the tissue release cytokines such as IL-1 and TNFα, which in turn leads to production of chemokines that bind to proteoglycans forming gradient in the inflamed tissue and along the endothelial wall.[26] Inflammatory cytokines induce the immediate expression of P-selectin on endothelial cell surfaces and P-selectin binds weakly to carbohydrate ligands on the surface of leukocytes and causes them to "roll" along the endothelial surface as bonds are made and broken. Cytokines released from injured cells induce the expression of E-selectin on endothelial cells, which functions similarly to P-selectin. Cytokines also induce the expression of integrin ligands such as ICAM-1 and VCAM-1 on endothelial cells, which mediate the adhesion and further slow leukocytes down. These weakly bound leukocytes are free to detach if not activated by chemokines produced in injured tissue after signal transduction via respective G protein-coupled receptors that activates integrins on the leukocyte surface for firm adhesion. Such activation increases the affinity of bound integrin receptors for ICAM-1 and VCAM-1 on the endothelial cell surface, firmly binding the leukocytes to the endothelium.
  2. Migration across the endothelium, known as transmigration, via the process of diapedesis: Chemokine gradients stimulate the adhered leukocytes to move between adjacent endothelial cells. The endothelial cells retract and the leukocytes pass through the basement membrane into the surrounding tissue using adhesion molecules such as ICAM-1.[29]
  3. Movement of leukocytes within the tissue via chemotaxis: Leukocytes reaching the tissue interstitium bind to extracellular matrix proteins via expressed integrins and CD44 to prevent them from leaving the site. A variety of molecules behave as chemoattractants, for example, C3a or C5a (the anaphylatoxins), and cause the leukocytes to move along a chemotactic gradient towards the source of inflammation.

Phagocytosis

[edit]

Extravasated neutrophils in the cellular phase come into contact with microbes at the inflamed tissue. Phagocytes express cell-surface endocytic pattern recognition receptors (PRRs) that have affinity and efficacy against non-specific microbe-associated molecular patterns (PAMPs). Most PAMPs that bind to endocytic PRRs and initiate phagocytosis are cell wall components, including complex carbohydrates such as mannans and β-glucans, lipopolysaccharides (LPS), peptidoglycans, and surface proteins. Endocytic PRRs on phagocytes reflect these molecular patterns, with C-type lectin receptors binding to mannans and β-glucans, and scavenger receptors binding to LPS.

Upon endocytic PRR binding, actin-myosin cytoskeletal rearrangement adjacent to the plasma membrane occurs in a way that endocytoses the plasma membrane containing the PRR-PAMP complex, and the microbe. Phosphatidylinositol and Vps34-Vps15-Beclin1 signalling pathways have been implicated to traffic the endocytosed phagosome to intracellular lysosomes, where fusion of the phagosome and the lysosome produces a phagolysosome. The reactive oxygen species, superoxides and hypochlorite bleach within the phagolysosomes then kill microbes inside the phagocyte.

Phagocytic efficacy can be enhanced by opsonization. Plasma derived complement C3b and antibodies that exude into the inflamed tissue during the vascular phase bind to and coat the microbial antigens. As well as endocytic PRRs, phagocytes also express opsonin receptors Fc receptor and complement receptor 1 (CR1), which bind to antibodies and C3b, respectively. The co-stimulation of endocytic PRR and opsonin receptor increases the efficacy of the phagocytic process, enhancing the lysosomal elimination of the infective agent.

Cell-derived mediators

[edit]

* non-exhaustive list

Name Type Source Description
Lysosome granules Enzymes Granulocytes These cells contain a large variety of enzymes that perform a number of functions. Granules can be classified as either specific or azurophilic depending upon the contents, and are able to break down a number of substances, some of which may be plasma-derived proteins that allow these enzymes to act as inflammatory mediators.
GM-CSF Glycoprotein Macrophages, monocytes, T-cells, B-cells, and tissue-resident cells Elevated GM-CSF has been shown to contribute to inflammation in inflammatory arthritis, osteoarthritis, colitis asthma, obesity, and COVID-19.
Histamine Monoamine Mast cells and basophils Stored in preformed granules, histamine is released in response to a number of stimuli. It causes arteriole dilation, increased venous permeability, and a wide variety of organ-specific effects.
IFN-γ Cytokine T-cells, NK cells Antiviral, immunoregulatory, and anti-tumour properties. This interferon was originally called macrophage-activating factor, and is especially important in the maintenance of chronic inflammation.
IL-6 Cytokine and Myokine Macrophages, osteoblasts, adipocytes, and smooth muscle cells (cytokine) Skeletal muscle cells (myokine) Pro-inflammatory cytokine secreted by macrophages in response to pathogen-associated molecular patterns (PAMPs); pro-inflammatory cytokine secreted by adipocytes, especially in obesity; anti-inflammatory myokine secreted by skeletal muscle cells in response to exercise.
IL-8 Chemokine Primarily macrophages Activation and chemoattraction of neutrophils, with a weak effect on monocytes and eosinophils.
Leukotriene B4 Eicosanoid Leukocytes, cancer cells Able to mediate leukocyte adhesion and activation, allowing them to bind to the endothelium and migrate across it. In neutrophils, it is also a potent chemoattractant, and is able to induce the formation of reactive oxygen species and the release of lysosomal enzymes by these cells.
LTC4, LTD4 Eicosanoid eosinophils, mast cells, macrophages These three Cysteine-containing leukotrienes contract lung airways, increase micro-vascular permeability, stimulate mucus secretion, and promote eosinophil-based inflammation in the lung, skin, nose, eye, and other tissues.
5-oxo-eicosatetraenoic acid Eicosanoid Leukocytes, cancer cells Potent stimulator of neutrophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation; monocyte chemotaxis; and with even greater potency eosinophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation.
5-HETE Eicosanoid Leukocytes Metabolic precursor to 5-Oxo-eicosatetraenoic acid, it is a less potent stimulator of neutrophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation; monocyte chemotaxis; and eosinophil chemotaxis, lysosome enzyme release, and reactive oxygen species formation.
Prostaglandins Eicosanoid Mast cells A group of lipids that can cause vasodilation, fever, and pain.
Nitric oxide Soluble gas Macrophages, endothelial cells, some neurons Potent vasodilator, relaxes smooth muscle, reduces platelet aggregation, aids in leukocyte recruitment, direct antimicrobial activity in high concentrations.
TNF-α and IL-1 Cytokines Primarily macrophages Both affect a wide variety of cells to induce many similar inflammatory reactions: fever, production of cytokines, endothelial gene regulation, chemotaxis, leukocyte adherence, activation of fibroblasts. Responsible for the systemic effects of inflammation, such as loss of appetite and increased heart rate. TNF-α inhibits osteoblast differentiation.
Tryptase Enzymes Mast Cells This serine protease is believed to be exclusively stored in mast cells and secreted, along with histamine, during mast cell activation.[30][31][32]

Morphologic patterns

[edit]

Specific patterns of acute and chronic inflammation are seen during particular situations that arise in the body, such as when inflammation occurs on an epithelial surface, or pyogenic bacteria are involved.

  • Granulomatous inflammation: Characterised by the formation of granulomas, they are the result of a limited but diverse number of diseases, which include among others tuberculosis, leprosy, sarcoidosis, and syphilis.
  • Fibrinous inflammation: Inflammation resulting in a large increase in vascular permeability allows fibrin to pass through the blood vessels. If an appropriate procoagulative stimulus is present, such as cancer cells,[9] a fibrinous exudate is deposited. This is commonly seen in serous cavities, where the conversion of fibrinous exudate into a scar can occur between serous membranes, limiting their function. The deposit sometimes forms a pseudomembrane sheet. During inflammation of the intestine (pseudomembranous colitis), pseudomembranous tubes can be formed.
  • Purulent inflammation: Inflammation resulting in large amount of pus, which consists of neutrophils, dead cells, and fluid. Infection by pyogenic bacteria such as staphylococci is characteristic of this kind of inflammation. Large, localised collections of pus enclosed by surrounding tissues are called abscesses.
  • Serous inflammation: Characterised by the copious effusion of non-viscous serous fluid, commonly produced by mesothelial cells of serous membranes, but may be derived from blood plasma. Skin blisters exemplify this pattern of inflammation.
  • Ulcerative inflammation: Inflammation occurring near an epithelium can result in the necrotic loss of tissue from the surface, exposing lower layers. The subsequent excavation in the epithelium is known as an ulcer.

Disorders

[edit]
Asthma is considered an inflammatory-mediated disorder. On the right is an inflamed airway due to asthma.
Colitis (inflammation of the colon) caused by Crohn's disease.

Inflammatory abnormalities are a large group of disorders that underlie a vast variety of human diseases. The immune system is often involved with inflammatory disorders, as demonstrated in both allergic reactions and some myopathies, with many immune system disorders resulting in abnormal inflammation. Non-immune diseases with causal origins in inflammatory processes include cancer, atherosclerosis, and ischemic heart disease.[9]

Examples of disorders associated with inflammation include:

Atherosclerosis

[edit]

Atherosclerosis, formerly considered a lipid storage disorder, is now understood as a chronic inflammatory condition involving the arterial walls.[33] Research has established a fundamental role for inflammation in mediating all stages of atherosclerosis from initiation through progression and, ultimately, the thrombotic complications from it.[33] These new findings reveal links between traditional risk factors like cholesterol levels and the underlying mechanisms of atherogenesis.

Clinical studies have shown that this emerging biology of inflammation in atherosclerosis applies directly to people.[33] For instance, elevation in markers of inflammation predicts outcomes of people with acute coronary syndromes, independently of myocardial damage. In addition, low-grade chronic inflammation, as indicated by levels of the inflammatory marker C-reactive protein, prospectively defines risk of atherosclerotic complications, thus adding to prognostic information provided by traditional risk factors, such as LDL levels.[34][33]

Moreover, certain treatments that reduce coronary risk also limit inflammation. Notably, lipid-lowering medications such as statins have shown anti-inflammatory effects, which may contribute to their efficacy beyond just lowering LDL levels.[35] This emerging understanding of inflammation's role in atherosclerosis has had significant clinical implications, influencing both risk stratification and therapeutic strategies.

Emerging treatments

[edit]

Recent developments in the treatment of atherosclerosis have focused on addressing inflammation directly. New anti-inflammatory drugs, such as monoclonal antibodies targeting IL-1β, have been studied in large clinical trials, showing promising results in reducing cardiovascular events.[36] These drugs offer a potential new avenue for treatment, particularly for patients who do not respond adequately to statins. However, concerns about long-term safety and cost remain significant barriers to widespread adoption.

Connection to depression

[edit]

Inflammatory processes can be triggered by negative cognition or their consequences, such as stress, violence, or deprivation. Negative cognition may therefore contribute to inflammation, which in turn can lead to depression. A 2019 meta-analysis found that chronic inflammation is associated with a 30% increased risk of developing major depressive disorder, supporting the link between inflammation and mental health.[37]

Allergy

[edit]

An allergic reaction, formally known as type 1 hypersensitivity, is the result of an inappropriate immune response triggering inflammation, vasodilation, and nerve irritation. A common example is hay fever, which is caused by a hypersensitive response by mast cells to allergens. Pre-sensitised mast cells respond by degranulating, releasing vasoactive chemicals such as histamine. These chemicals propagate an excessive inflammatory response characterised by blood vessel dilation, production of pro-inflammatory molecules, cytokine release, and recruitment of leukocytes.[9] Severe inflammatory response may mature into a systemic response known as anaphylaxis.

Myopathies

[edit]

Inflammatory myopathies are caused by the immune system inappropriately attacking components of muscle, leading to signs of muscle inflammation. They may occur in conjunction with other immune disorders, such as systemic sclerosis, and include dermatomyositis, polymyositis, and inclusion body myositis.[9]

Leukocyte defects

[edit]

Due to the central role of leukocytes in the development and propagation of inflammation, defects in leukocyte functionality often result in a decreased capacity for inflammatory defense with subsequent vulnerability to infection.[9] Dysfunctional leukocytes may be unable to correctly bind to blood vessels due to surface receptor mutations, digest bacteria (Chédiak–Higashi syndrome), or produce microbicides (chronic granulomatous disease). In addition, diseases affecting the bone marrow may result in abnormal or few leukocytes.

Pharmacological

[edit]

Certain drugs or exogenous chemical compounds are known to affect inflammation. Vitamin A deficiency, for example, causes an increase in inflammatory responses,[38] and anti-inflammatory drugs work specifically by inhibiting the enzymes that produce inflammatory eicosanoids. Additionally, certain illicit drugs such as cocaine and ecstasy may exert some of their detrimental effects by activating transcription factors intimately involved with inflammation (e.g. NF-κB).[39][40]

Cancer

[edit]

Inflammation orchestrates the microenvironment around tumours, contributing to proliferation, survival and migration.[41] Cancer cells use selectins, chemokines and their receptors for invasion, migration and metastasis.[42] On the other hand, many cells of the immune system contribute to cancer immunology, suppressing cancer.[43] Molecular intersection between receptors of steroid hormones, which have important effects on cellular development, and transcription factors that play key roles in inflammation, such as NF-κB, may mediate some of the most critical effects of inflammatory stimuli on cancer cells.[44] This capacity of a mediator of inflammation to influence the effects of steroid hormones in cells is very likely to affect carcinogenesis. On the other hand, due to the modular nature of many steroid hormone receptors, this interaction may offer ways to interfere with cancer progression, through targeting of a specific protein domain in a specific cell type. Such an approach may limit side effects that are unrelated to the tumor of interest, and may help preserve vital homeostatic functions and developmental processes in the organism.

There is some evidence from 2009 to suggest that cancer-related inflammation (CRI) may lead to accumulation of random genetic alterations in cancer cells.[45][needs update]

Role in cancer

[edit]

In 1863, Rudolf Virchow hypothesized that the origin of cancer was at sites of chronic inflammation.[42][46] As of 2012, chronic inflammation was estimated to contribute to approximately 15% to 25% of human cancers.[46][47]

Mediators and DNA damage in cancer

[edit]

An inflammatory mediator is a messenger that acts on blood vessels and/or cells to promote an inflammatory response.[48] Inflammatory mediators that contribute to neoplasia include prostaglandins, inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-15 and chemokines such as IL-8 and GRO-alpha.[49][46] These inflammatory mediators, and others, orchestrate an environment that fosters proliferation and survival.[42][49]

Inflammation also causes DNA damages due to the induction of reactive oxygen species (ROS) by various intracellular inflammatory mediators.[42][49][46] In addition, leukocytes and other phagocytic cells attracted to the site of inflammation induce DNA damages in proliferating cells through their generation of ROS and reactive nitrogen species (RNS). ROS and RNS are normally produced by these cells to fight infection.[42] ROS, alone, cause more than 20 types of DNA damage.[50] Oxidative DNA damages cause both mutations[51] and epigenetic alterations.[52][46][53] RNS can also cause mutagenic DNA damages.[54]

A normal cell may undergo carcinogenesis to become a cancer cell if it is frequently subjected to DNA damage during long periods of chronic inflammation. DNA damages may cause genetic mutations due to inaccurate repair. In addition, mistakes in the DNA repair process may cause epigenetic alterations.[46][49][53] Mutations and epigenetic alterations that are replicated and provide a selective advantage during somatic cell proliferation may be carcinogenic.

Genome-wide analyses of human cancer tissues reveal that a single typical cancer cell may possess roughly 100 mutations in coding regions, 10–20 of which are "driver mutations" that contribute to cancer development.[46] However, chronic inflammation also causes epigenetic changes such as DNA methylations, that are often more common than mutations. Typically, several hundreds to thousands of genes are methylated in a cancer cell (see DNA methylation in cancer). Sites of oxidative damage in chromatin can recruit complexes that contain DNA methyltransferases (DNMTs), a histone deacetylase (SIRT1), and a histone methyltransferase (EZH2), and thus induce DNA methylation.[46][55][56] DNA methylation of a CpG island in a promoter region may cause silencing of its downstream gene (see CpG site and regulation of transcription in cancer). DNA repair genes, in particular, are frequently inactivated by methylation in various cancers (see hypermethylation of DNA repair genes in cancer). A 2018 report[57] evaluated the relative importance of mutations and epigenetic alterations in progression to two different types of cancer. This report showed that epigenetic alterations were much more important than mutations in generating gastric cancers (associated with inflammation).[58] However, mutations and epigenetic alterations were of roughly equal importance in generating esophageal squamous cell cancers (associated with tobacco chemicals and acetaldehyde, a product of alcohol metabolism).

HIV and AIDS

[edit]

It has long been recognized that infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation.[59][60][61] A substantial body of evidence implicates chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.[59][62] Many now regard HIV infection not only as an evolving virus-induced immunodeficiency, but also as chronic inflammatory disease.[63] Even after the introduction of effective antiretroviral therapy (ART) and effective suppression of viremia in HIV-infected individuals, chronic inflammation persists. Animal studies also support the relationship between immune activation and progressive cellular immune deficiency: SIVsm infection of its natural nonhuman primate hosts, the sooty mangabey, causes high-level viral replication but limited evidence of disease.[64][65] This lack of pathogenicity is accompanied by a lack of inflammation, immune activation and cellular proliferation. In sharp contrast, experimental SIVsm infection of rhesus macaque produces immune activation and AIDS-like disease with many parallels to human HIV infection.[66]

Delineating how CD4 T cells are depleted and how chronic inflammation and immune activation are induced lies at the heart of understanding HIV pathogenesis—one of the top priorities for HIV research by the Office of AIDS Research, National Institutes of Health. Recent studies demonstrated that caspase-1-mediated pyroptosis, a highly inflammatory form of programmed cell death, drives CD4 T-cell depletion and inflammation by HIV.[67][68][69] These are the two signature events that propel HIV disease progression to AIDS. Pyroptosis appears to create a pathogenic vicious cycle in which dying CD4 T cells and other immune cells (including macrophages and neutrophils) release inflammatory signals that recruit more cells into the infected lymphoid tissues to die. The feed-forward nature of this inflammatory response produces chronic inflammation and tissue injury.[70] Identifying pyroptosis as the predominant mechanism that causes CD4 T-cell depletion and chronic inflammation, provides novel therapeutic opportunities, namely caspase-1 which controls the pyroptotic pathway. In this regard, pyroptosis of CD4 T cells and secretion of pro-inflammatory cytokines such as IL-1β and IL-18 can be blocked in HIV-infected human lymphoid tissues by addition of the caspase-1 inhibitor VX-765,[67] which has already proven to be safe and well tolerated in phase II human clinical trials.[71] These findings could propel development of an entirely new class of "anti-AIDS" therapies that act by targeting the host rather than the virus. Such agents would almost certainly be used in combination with ART. By promoting "tolerance" of the virus instead of suppressing its replication, VX-765 or related drugs may mimic the evolutionary solutions occurring in multiple monkey hosts (e.g. the sooty mangabey) infected with species-specific lentiviruses that have led to a lack of disease, no decline in CD4 T-cell counts, and no chronic inflammation.

Resolution

[edit]

The inflammatory response must be actively terminated when no longer needed to prevent unnecessary "bystander" damage to tissues.[9] Failure to do so results in chronic inflammation, and cellular destruction. Resolution of inflammation occurs by different mechanisms in different tissues. Mechanisms that serve to terminate inflammation include:[9][72]

Acute inflammation normally resolves by mechanisms that have remained somewhat elusive. Emerging evidence now suggests that an active, coordinated program of resolution initiates in the first few hours after an inflammatory response begins. After entering tissues, granulocytes promote the switch of arachidonic acid–derived prostaglandins and leukotrienes to lipoxins, which initiate the termination sequence. Neutrophil recruitment thus ceases and programmed death by apoptosis is engaged. These events coincide with the biosynthesis, from omega-3 polyunsaturated fatty acids, of resolvins and protectins, which critically shorten the period of neutrophil infiltration by initiating apoptosis. As a consequence, apoptotic neutrophils undergo phagocytosis by macrophages, leading to neutrophil clearance and release of anti-inflammatory and reparative cytokines such as transforming growth factor-β1. The anti-inflammatory program ends with the departure of macrophages through the lymphatics.[83]

Connection to depression

[edit]

There is evidence for a link between inflammation and depression.[84] Inflammatory processes can be triggered by negative cognitions or their consequences, such as stress, violence, or deprivation. Thus, negative cognitions can cause inflammation that can, in turn, lead to depression.[85][86][dubiousdiscuss] In addition, there is increasing evidence that inflammation can cause depression because of the increase of cytokines, setting the brain into a "sickness mode".[87]

Classical symptoms of being physically sick, such as lethargy, show a large overlap in behaviors that characterize depression. Levels of cytokines tend to increase sharply during the depressive episodes of people with bipolar disorder and drop off during remission.[88] Furthermore, it has been shown in clinical trials that anti-inflammatory medicines taken in addition to antidepressants not only significantly improves symptoms but also increases the proportion of subjects positively responding to treatment.[89] Inflammations that lead to serious depression could be caused by common infections such as those caused by a virus, bacteria or even parasites.[90]

Connection to delirium

[edit]

There is evidence for a link between inflammation and delirium based on the results of a recent longitudinal study investigating CRP in COVID-19 patients.[91]

Systemic effects

[edit]

An infectious organism can escape the confines of the immediate tissue via the circulatory system or lymphatic system, where it may spread to other parts of the body. If an organism is not contained by the actions of acute inflammation, it may gain access to the lymphatic system via nearby lymph vessels. An infection of the lymph vessels is known as lymphangitis, and infection of a lymph node is known as lymphadenitis. When lymph nodes cannot destroy all pathogens, the infection spreads further. A pathogen can gain access to the bloodstream through lymphatic drainage into the circulatory system.

When inflammation overwhelms the host, systemic inflammatory response syndrome is diagnosed. When it is due to infection, the term sepsis is applied, with the terms bacteremia being applied specifically for bacterial sepsis and viremia specifically to viral sepsis. Vasodilation and organ dysfunction are serious problems associated with widespread infection that may lead to septic shock and death.[92]

Acute-phase proteins

[edit]

Inflammation also is characterized by high systemic levels of acute-phase proteins. In acute inflammation, these proteins prove beneficial; however, in chronic inflammation, they can contribute to amyloidosis.[9] These proteins include C-reactive protein, serum amyloid A, and serum amyloid P, which cause a range of systemic effects including:[9]

Leukocyte numbers

[edit]

Inflammation often affects the numbers of leukocytes present in the body:

  • Leukocytosis is often seen during inflammation induced by infection, where it results in a large increase in the amount of leukocytes in the blood, especially immature cells. Leukocyte numbers usually increase to between 15 000 and 20 000 cells per microliter, but extreme cases can see it approach 100 000 cells per microliter.[9] Bacterial infection usually results in an increase of neutrophils, creating neutrophilia, whereas diseases such as asthma, hay fever, and parasite infestation result in an increase in eosinophils, creating eosinophilia.[9]
  • Leukopenia can be induced by certain infections and diseases, including viral infection, Rickettsia infection, some protozoa, tuberculosis, and some cancers.[9]

Interleukins and obesity

[edit]

With the discovery of interleukins (IL), the concept of systemic inflammation developed. Although the processes involved are identical to tissue inflammation, systemic inflammation is not confined to a particular tissue but involves the endothelium and other organ systems.

Chronic inflammation is widely observed in obesity.[93][94] Obese people commonly have many elevated markers of inflammation, including:[95][96]

Low-grade chronic inflammation is characterized by a two- to threefold increase in the systemic concentrations of cytokines such as TNF-α, IL-6, and CRP.[99] Waist circumference correlates significantly with systemic inflammatory response.[100]

Loss of white adipose tissue reduces levels of inflammation markers.[93] As of 2017 the association of systemic inflammation with insulin resistance and type 2 diabetes, and with atherosclerosis was under preliminary research, although rigorous clinical trials had not been conducted to confirm such relationships.[101]

C-reactive protein (CRP) is generated at a higher level in obese people, and may increase the risk for cardiovascular diseases.[102]

Outcomes

[edit]

The outcome in a particular circumstance will be determined by the tissue in which the injury has occurred—and the injurious agent that is causing it. Here are the possible outcomes to inflammation:[9]

  1. Resolution
    The complete restoration of the inflamed tissue back to a normal status. Inflammatory measures such as vasodilation, chemical production, and leukocyte infiltration cease, and damaged parenchymal cells regenerate. Such is usually the outcome when limited or short-lived inflammation has occurred.
  2. Fibrosis
    Large amounts of tissue destruction, or damage in tissues unable to regenerate, cannot be regenerated completely by the body. Fibrous scarring occurs in these areas of damage, forming a scar composed primarily of collagen. The scar will not contain any specialized structures, such as parenchymal cells, hence functional impairment may occur.
  3. Abscess formation
    A cavity is formed containing pus, an opaque liquid containing dead white blood cells and bacteria with general debris from destroyed cells.
  4. Chronic inflammation
    In acute inflammation, if the injurious agent persists then chronic inflammation will ensue. This process, marked by inflammation lasting many days, months or even years, may lead to the formation of a chronic wound. Chronic inflammation is characterised by the dominating presence of macrophages in the injured tissue. These cells are powerful defensive agents of the body, but the toxins they release—including reactive oxygen species—are injurious to the organism's own tissues as well as invading agents. As a consequence, chronic inflammation is almost always accompanied by tissue destruction.

Examples

[edit]

Inflammation is usually indicated by adding the suffix "itis", as shown below. However, some conditions, such as asthma and pneumonia, do not follow this convention. More examples are available at List of types of inflammation.

See also

[edit]

Notes

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Inflammation is a fundamental biological response of the to harmful stimuli, including pathogens, damaged cells, irritants, or toxins, aimed at protecting the body by eliminating the cause of and initiating the process. This response involves localized changes such as , increased , and recruitment of immune cells, leading to the classic cardinal signs of redness (rubor), (calor), swelling (tumor), (dolor), and sometimes loss of function. These signs arise from the release of mediators like , cytokines, and , which coordinate the inflammatory cascade. Inflammation manifests in two primary forms: acute and chronic. Acute inflammation is a rapid, short-term reaction, typically lasting hours to days, dominated by neutrophils and aimed at quick resolution to restore tissue homeostasis. In contrast, chronic inflammation develops more slowly over weeks, months, or years, involving monocytes, macrophages, and lymphocytes, and often persists when the initial trigger is not fully eliminated or due to autoimmune dysregulation. While acute inflammation is generally beneficial for defense and repair, chronic inflammation can become detrimental, contributing to tissue damage and the pathogenesis of numerous diseases. The clinical significance of inflammation extends to its role in both health maintenance and disease progression, influencing conditions from infections to chronic disorders. For instance, unresolved inflammation is implicated in over 50% of global deaths, including cardiovascular diseases, , cancer, and neurodegenerative conditions like Alzheimer's. Environmental factors, such as and chemical exposures, can exacerbate inflammatory responses, heightening risks for , heart disease, and even certain cancers. Elevated biomarkers like (CRP) serve as indicators of and predictors of adverse outcomes in these pathologies. Understanding inflammation's mechanisms has driven therapeutic advancements, including anti-inflammatory drugs like NSAIDs and biologics targeting specific cytokines.

Fundamentals

Definition

Inflammation is a fundamental protective response of the designed to eliminate harmful stimuli, such as pathogens or damaged cells, and to initiate the healing process. This complex biological reaction coordinates the activation of immune cells, including neutrophils and macrophages, alongside changes in blood vessels and the release of molecular mediators like cytokines and to localize and resolve the threat. The hallmark clinical signs of inflammation, articulated by the ancient Roman encyclopedist , encompass redness (rubor) due to , heat (calor) from increased blood flow, swelling (tumor) caused by fluid accumulation, and pain (dolor) resulting from irritation and . A fifth sign, loss of function (functio laesa), was later incorporated by the physician , reflecting impaired tissue utility during the response. These observable features underscore inflammation's role in alerting the body to while promoting repair. Inflammation manifests in two primary forms: local, which is restricted to the site of and typically resolves without broader impact, or systemic, which engages the entire through circulating mediators and can influence distant tissues. From an evolutionary perspective, inflammation emerged as an adaptive mechanism in multicellular organisms to defend against pathogens, physical injuries, and environmental toxins, thereby preserving tissue integrity and organismal survival across species.

Historical Context

The understanding of inflammation dates back to ancient civilizations, where early observers noted its observable signs without a mechanistic explanation. In the , , the Greek physician often regarded as the father of , described inflammation in terms of tissue changes such as redness, swelling, heat, and pain, using terms like rubor (redness), tumor (swelling), calor (heat), and dolor (pain), which laid the groundwork for later classifications. These observations were empirical, derived from clinical experience, and emphasized inflammation as a response to injury or imbalance in bodily humors. By the 1st century AD, the Roman encyclopedist formalized these into the four cardinal signs in his work De Medicina, providing a systematic description that influenced medical thought for centuries. The marked a shift toward microscopic and experimental investigations, revealing cellular processes underlying inflammation. In 1867, German pathologist Julius Cohnheim demonstrated —the migration of white blood cells from blood vessels into tissues—through innovative intravital microscopy experiments on frog tongues and mesentery, challenging earlier views of inflammation as merely a vascular event. Building on this, Ilya Metchnikoff advanced the cellular theory of immunity in the 1880s by discovering , the active engulfment of pathogens by leukocytes. contributed through his novel staining techniques to visualize and classify leukocytes, supporting the understanding of their roles in immune defense. These contributions transitioned inflammation from a descriptive to a process involving dynamic cellular movements. In the 20th century, biochemical discoveries illuminated the molecular mediators orchestrating inflammation. Prostaglandins, key lipid mediators, were first identified in the 1930s by Ulf von Euler from human seminal fluid and sheep prostate extracts, revealing their role in smooth muscle contraction and later in inflammatory responses. The 1970s and 1980s brought the isolation and characterization of interleukins and other cytokines, such as interleukin-1 (discovered as leukocytic pyrogen in the 1940s but molecularly defined in the 1980s) and interleukin-2 (identified in 1976 as a T-cell growth factor), which elucidated the signaling cascades amplifying inflammation. Cytokines, broadly recognized by the late 20th century, were shown to coordinate the inflammatory response through interconnected pathways. Mid-century research, particularly post-1950s advances in immunology, shifted emphasis from predominantly humoral theories—favoring soluble factors like antibodies—to cellular theories, integrating both but highlighting leukocytes and their mediators as central drivers.

Causes

Exogenous Causes

Exogenous causes of inflammation arise from external environmental factors that directly damage tissues or activate immune recognition, distinguishing them from internal physiological triggers. These factors encompass microbial invasions, physical injuries, and chemical exposures, each capable of initiating a protective inflammatory response to restore homeostasis. Microbial infections represent a leading exogenous inducer of inflammation, primarily through the recognition of pathogen-associated molecular patterns (PAMPs) on bacteria, viruses, fungi, and parasites by host pattern recognition receptors. Bacterial pathogens, such as Streptococcus pyogenes, provoke acute pharyngitis by adhering to throat mucosa and eliciting localized inflammation characterized by redness, swelling, and pain. Viral infections like influenza trigger robust respiratory inflammation via viral PAMPs, leading to symptoms including fever and airway hyperreactivity. Fungal agents, including Candida species, and parasitic organisms, such as helminths, similarly stimulate inflammatory cascades through their surface PAMPs, often resulting in tissue-specific responses like mucosal irritation or granuloma formation. For instance, bacterial obstruction of the appendix lumen, commonly by fecaliths harboring pathogens, causes acute appendicitis with intense localized inflammation. Physical agents induce inflammation via mechanical or thermal disruption of tissue barriers, prompting repair mechanisms. Trauma, such as cuts or blunt force, directly damages cells and vessels, initiating an inflammatory cascade to clear debris and promote healing. Burns from heat sources denature proteins and cause necrosis, leading to a graded inflammatory response proportional to tissue depth affected. Ionizing radiation generates free radicals that harm DNA and cellular structures, resulting in delayed or acute inflammation depending on exposure dose. Foreign bodies, exemplified by splinters or embedded debris, provoke persistent localized inflammation as immune cells encapsulate the intruder to prevent dissemination. Chemical irritants trigger inflammation through corrosive effects or reactions, often affecting skin or mucosal surfaces. Strong acids and alkalis cause immediate tissue and secondary inflammation by disrupting cellular membranes and balance. Toxins from environmental sources, including , induce and inflammatory mediator release. Allergens like , the in (), elicit , manifesting as with vesicular eruptions and intense pruritus. Similarly, nickel exposure in jewelry or tools commonly leads to chronic eczematous inflammation in sensitized individuals via hapten-mediated T-cell activation.

Endogenous Causes

Endogenous causes of inflammation arise from internal physiological disruptions or pathological processes within the body, distinct from external triggers, and often involve the release of endogenous molecules that alert the to cellular damage or dysfunction. These factors initiate inflammatory responses through mechanisms such as the recognition of damage-associated molecular patterns (DAMPs), which are intracellular components released by stressed or dying cells and recognized by receptors on immune cells. Tissue represents a primary endogenous cause, where due to ischemia or other internal insults leads to the liberation of DAMPs, thereby activating innate immune responses and promoting inflammation. For instance, in , ischemic of cardiac tissue releases DAMPs such as high-mobility group box 1 () and , which bind to receptors like (TLR4) on macrophages and endothelial cells, initiating a cascade of cytokine production including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). This sterile inflammation can exacerbate tissue damage and contribute to complications like if unresolved. Autoimmune reactions constitute another key endogenous trigger, occurring when the erroneously targets self-antigens, leading to persistent inflammation in affected tissues. In , for example, autoantibodies such as and anti-citrullinated protein antibodies (ACPAs) form immune complexes that deposit in the synovial joints, activating complement and recruiting neutrophils, which release pro-inflammatory mediators and perpetuate synovial inflammation. This dysregulated response involves T-cell activation and cytokine storms, particularly involving IL-6 and IL-17, driving joint destruction over time. Metabolic disturbances also provoke endogenous inflammation through the accumulation of aberrant metabolites that act as irritants to immune cells. Crystal-induced inflammation, as seen in , results from monosodium urate crystals formed due to , which are phagocytosed by macrophages, activating the and releasing IL-1β to cause acute inflammation. Similarly, in early , oxidized (oxLDL) accumulates in arterial walls, serving as a DAMP that stimulates endothelial cells and macrophages via scavenger receptors and TLRs, leading to formation and chronic vascular inflammation. These processes highlight how metabolic imbalances can initiate and sustain inflammatory states. Additional examples include , where premature activation of pancreatic leads to autodigestion of acinar cells, releasing enzymes like that damage surrounding tissue and trigger local inflammation through protease-activated receptors and release. In , immune dysregulation in the gut mucosa results in aberrant responses to commensal antigens, involving overproduction of pro-inflammatory s such as TNF-α and IL-23 by lamina propria T cells and , causing chronic intestinal inflammation. Such endogenous mechanisms underscore the body's intricate balance in immune surveillance, where internal derangements can escalate into pathological inflammation.

Classification

Acute Inflammation

Acute inflammation represents a rapid, short-term defensive response of the to harmful stimuli, such as pathogens or tissue , designed to eliminate the inciting agent and initiate repair processes. It typically onset within minutes to hours following the trigger and lasts for a few days, allowing for the containment and clearance of the threat while minimizing damage to surrounding tissues. The process begins with an initial vascular response, characterized by and increased permeability of blood vessels, which facilitates the delivery of plasma proteins and immune cells to the affected site. This is rapidly followed by a neutrophil-dominated cellular infiltration, where polymorphonuclear leukocytes (neutrophils) are the predominant cells recruited via chemotactic signals like cytokines and ; these cells engulf and destroy pathogens through and release of substances. If successful, acute inflammation progresses to a resolution phase involving the clearance of cellular debris and apoptotic neutrophils primarily through macrophage-mediated , alongside the downregulation of pro-inflammatory mediators to restore tissue homeostasis. , such as resolvins derived from omega-3 fatty acids, actively promote this phase by enhancing and shifting macrophages toward a reparative . Common examples include the inflammatory response in , where acute inflammation aids in debris removal and epithelial regeneration; acute , marked by neutrophil accumulation in the appendix wall; and bacterial , involving rapid neutrophil influx into the alveoli to combat . These responses often manifest with the classic cardinal signs of redness, heat, swelling, , and loss of function, particularly in superficial tissues.

Chronic Inflammation

Chronic inflammation represents a prolonged inflammatory response that persists for months to years, distinguishing it from the shorter duration of acute inflammation. This sustained state arises primarily from persistent stimuli, such as microbial infections (e.g., ), or from inadequate resolution of initial inflammatory triggers, including autoimmune reactions or exposure to non-degradable substances. The failure of resolution mechanisms, such as impaired clearance of pathogens or dysregulated immune signaling, perpetuates the inflammatory environment, leading to ongoing tissue injury and attempted repair. Unlike acute inflammation, which relies on innate immune effectors, chronic inflammation involves adaptive immune elements that contribute to its longevity and tissue-altering effects. A hallmark of chronic inflammation is the shift in cellular infiltrates toward mononuclear cells, predominantly macrophages and lymphocytes, which replace the neutrophils dominant in acute phases. Macrophages, by persistent antigens, release pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), sustaining leukocyte recruitment and amplifying the response. Lymphocytes, including T cells, further orchestrate this process through antigen-specific , promoting the differentiation of macrophages into epithelioid cells or multinucleated giant cells. This cellular composition drives the formation of granulomas—organized aggregates of macrophages and lymphocytes that wall off indigestible material, as seen in where they contain mycobacteria—or excessive (ECM) deposition leading to . Tissue remodeling in chronic inflammation encompasses , scarring, and progressive , reflecting the balance between destructive inflammation and reparative processes. New blood vessel formation, stimulated by cytokines such as (VEGF) from macrophages, supplies nutrients to the inflamed site but also facilitates further immune cell infiltration. Over time, activated fibroblasts produce excessive and other ECM components, resulting in and that replaces normal , potentially impairing function— for instance, leading to in chronic through portal tract . In , chronic inflammation promotes plaque buildup via mononuclear cell accumulation and ECM remodeling in arterial walls, while in , it manifests as synovial proliferation and formation. Granulomatous patterns, such as those in , exemplify organized remodeling efforts to isolate pathogens.

Pathophysiology

Vascular Component

The vascular component of inflammation involves a series of hemodynamic alterations in the microvasculature that facilitate the delivery of plasma proteins, fluid, and immune mediators to the site of injury or infection. These changes are initiated rapidly following tissue damage or pathogen recognition, primarily through the release of local mediators that act on endothelial cells and vascular smooth muscle. The key vascular responses include vasodilation, increased permeability, and blood flow stasis, which collectively contribute to the cardinal signs of inflammation such as redness (rubor), heat (calor), and swelling (tumor). Vasodilation, the widening of arterioles and capillaries, is a primary early event that increases blood flow to the inflamed area, enhancing the supply of oxygen, nutrients, and inflammatory mediators while causing the observed and warmth. This process is mediated by several key chemical signals: , released from mast cells and , binds to H1 receptors on endothelial cells to trigger relaxation of vascular ; (NO), produced by endothelial in response to or mediators like , diffuses to cells to induce cyclic GMP-dependent relaxation; and prostaglandins, particularly PGE2 synthesized via pathways in activated cells, potentiate these effects by sensitizing vessels to other vasodilators. These mediators act synergistically, with and NO often providing the initial rapid response within minutes, while prostaglandins sustain the dilation over hours. Increased follows and is essential for allowing plasma components to escape into the extravascular space, forming the basis for tissue swelling. Inflammatory mediators such as , leukotrienes, and cytokines induce transient contraction of endothelial cells, particularly in postcapillary venules, leading to the formation of intercellular gaps typically 0.1–0.5 μm in diameter. These gaps disrupt the endothelial barrier's tight junctions and adherens junctions, enabling the leakage of plasma proteins (e.g., fibrinogen and immunoglobulins) and fluid, which increases interstitial and drives formation. This permeability change is reversible in acute inflammation but can become prolonged in chronic settings due to cytoskeletal remodeling. The process is tightly regulated to prevent excessive leakage, with endothelial and junctional proteins like playing protective roles. As inflammation progresses, the influx of protein-rich plasma into tissues raises the of in the microvasculature, resulting in stasis or slowed flow, particularly in venules. This hemodynamic shift occurs because the increased diameter from combined with plasma leakage dilutes red cells centrally while concentrating formed elements peripherally, promoting formation and reduced flow velocity. Stasis facilitates leukocyte margination, where adhere to the vessel wall, setting the stage for subsequent without directly involving cellular migration mechanisms. In severe cases, prolonged stasis can contribute to local hypoxia and , amplifying tissue damage. These vascular alterations culminate in the formation of an , a protein-rich that accumulates in the interstitial spaces of inflamed tissues, distinguishing inflammatory from the low-protein seen in non-inflammatory conditions like . typically contains 3–5 g/dL of protein (compared to <1 g/dL in transudates), along with electrolytes, clotting factors, and complement components, which support deposition for microbial containment and facilitate delivery. The protein leakage, driven by the permeability changes described, creates a viscous, fibrinous matrix that aids in walling off the injury site, though excessive can impair tissue function by compressing structures or promoting if unresolved.

Cellular Component

The cellular component of inflammation encompasses the recruitment, , and effector functions of leukocytes, which are essential for containing and eliminating injurious agents at the site of tissue damage or . Leukocytes, primarily neutrophils, monocytes/macrophages, and lymphocytes, migrate from the bloodstream into inflamed tissues through a tightly regulated multistep known as . This is facilitated by endothelial in response to inflammatory signals, enabling leukocyte-endothelium interactions. Leukocyte extravasation begins with margination, where circulating leukocytes are displaced from the central flow of blood toward the vessel wall due to slowed blood flow in postcapillary venules. This is followed by rolling, a reversible tethering of leukocytes along the mediated by selectins—P-selectin and expressed on activated endothelial cells, and on leukocytes—which bind carbohydrate ligands such as . Firm then occurs as presented on the endothelial surface activate leukocyte (e.g., LFA-1 and Mac-1), leading to high-affinity binding to endothelial intercellular molecule-1 () and vascular cell molecule-1 (). Finally, transmigration, or diapedesis, allows leukocytes to squeeze through endothelial junctions or, less commonly, via a transcellular route, guided by and CD99 interactions, to enter the interstitial space. Once at the inflammatory site, leukocytes execute key effector functions, including , whereby neutrophils and macrophages engulf and destroy pathogens, apoptotic cells, and debris. is enhanced by opsonization, in which antibodies (IgG) and complement proteins (e.g., C3b) coat targets to facilitate recognition via Fcγ receptors and complement receptors on . Neutrophils, as rapid responders, perform efficient of opsonized , releasing antimicrobial granules and to kill engulfed material. Activated leukocytes further amplify the inflammatory response by secreting cell-derived mediators. Cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), produced mainly by macrophages, promote endothelial activation, fever, and further leukocyte recruitment. , including IL-8, direct leukocyte to the site, while lipid mediators like leukotrienes (e.g., LTB4) enhance and stimulate . The composition of infiltrating cells differs between acute and chronic inflammation. In acute inflammation, neutrophils predominate in the early phase (within hours), providing rapid antimicrobial defense before undergoing . Macrophages arrive later, phagocytosing apoptotic neutrophils and transitioning the response toward resolution. In chronic inflammation, which persists beyond days to weeks, macrophages become the dominant cell type, alongside lymphocytes, sustaining tissue remodeling and through persistent mediator release.

Clinical and Morphologic Features

Cardinal Signs and Symptoms

The cardinal signs of inflammation, originally described by the Roman encyclopedist Aulus Cornelius Celsus around 25 AD, comprise four local manifestations: redness (rubor), heat (calor), swelling (tumor), and pain (dolor). These signs arise from the vascular and cellular responses to injury or infection, providing clinicians with observable indicators of the inflammatory process. Traditionally attributed to the physician Galen in the 2nd century AD, though modern scholarship suggests it may have been added later by figures such as Rudolf Virchow in the 19th century, a fifth sign, loss of function (functio laesa), emphasizes the impairment in tissue utility due to the combined effects of pain and mechanical disruption from swelling. Redness results from of arterioles and capillaries, which increases blood flow to the affected area and causes hyperemia. stems from this enhanced , delivering warmer and elevating local temperature, particularly noticeable in peripheral tissues. Swelling occurs due to increased , allowing plasma proteins and fluid to leak into the interstitial space, forming that distends tissues. Pain arises from the release of chemical mediators such as and (PGE2), which directly stimulate nociceptors or sensitize them to mechanical and thermal stimuli. Loss of function follows as a consequence of , -induced pressure on nerves and tissues, and stiffness, limiting movement or organ performance. In addition to these local signs, inflammation often produces systemic symptoms. Fever develops when endogenous pyrogens like interleukin-1 (IL-1) act on the , resetting the body's thermoregulatory set point and triggering heat conservation mechanisms. , characterized by fatigue and general discomfort, results from the central actions of proinflammatory cytokines such as IL-1 and IL-6, which induce behavioral changes akin to . Local signs like and swelling predominate at the site of , whereas systemic effects such as fever reflect broader cytokine-mediated responses. Assessment of these signs relies primarily on clinical observation, including for warmth and tenderness, for redness and swelling, and reports of and functional impairment. modalities, such as (MRI), can confirm by detecting fluid accumulation in tissues, aiding in cases where clinical signs are subtle.

Morphologic Patterns

Morphologic patterns of inflammation refer to the distinct histologic appearances observed in inflamed tissues, primarily determined by the nature and quantity of the as well as the predominant cellular infiltrates. These patterns provide insights into the underlying pathologic processes and help in classifying the type and severity of the inflammatory response. They are identified through microscopic examination of tissue samples and are crucial for differentiating acute from more persistent forms of inflammation. Serous inflammation is characterized by the accumulation of a thin, watery composed mainly of serum-like fluid with few cells, resulting from mild changes. This pattern is commonly seen in serosal cavities or surfaces, such as the formation of blisters in second-degree burns where the separates the from the . Histologically, it appears as clear, protein-poor fluid without significant cellular components. Fibrinous inflammation involves the deposition of a thick, rich in due to extensive vascular leakage and activation of the cascade. It typically occurs on serosal surfaces, as in fibrinous associated with , where the forms a shaggy layer over the affected tissue. Under the , the appears as pink, thread-like strands that may organize into fibrous tissue if the inflammation persists. Suppurative or purulent inflammation is marked by the production of , an consisting of neutrophils, necrotic debris, and edema fluid, often triggered by pyogenic bacterial infections. This pattern manifests as localized collections like abscesses, where a central zone of is surrounded by a wall of neutrophils and fibroblasts. Histologic examination reveals dense neutrophilic infiltrates with karyorrhectic debris, distinguishing it from other types. Granulomatous inflammation features organized aggregates of macrophages, often termed granulomas, formed in response to persistent antigens that resist , representing a chronic inflammatory pattern. These collections include epithelioid histiocytes with elongated nuclei and abundant cytoplasm, sometimes fused into multinucleated giant cells, as seen in where central may be present. Microscopically, the granulomas are compact, with surrounding lymphocytes, and lack the acute neutrophilic response of suppurative patterns. Ulcerative inflammation describes the pattern where inflammation leads to the sloughing of necrotic tissue, creating a local defect or on or mucosal surfaces due to deep tissue destruction. This occurs in areas of chronic , resulting in a base of covered by fibrinopurulent . Histologically, it shows full-thickness epithelial loss with underlying inflammation and . The identification of these morphologic patterns relies on diagnostic tools such as tissue biopsy, which provides samples for histologic analysis, and light microscopy with special stains to highlight specific features like or microbial elements. These methods allow pathologists to correlate the observed patterns with clinical contexts, aiding in accurate .

Systemic Effects

Acute-Phase Response

The acute-phase response represents a systemic reaction to inflammation, characterized by liver-mediated alterations in the synthesis of plasma proteins and metabolic shifts that support host defense and tissue repair. Primarily orchestrated by hepatocytes, this response involves the rapid production or suppression of specific proteins in circulation, driven by pro-inflammatory cytokines such as interleukin-6 (IL-6). Positive acute-phase proteins, whose serum concentrations increase by at least 25% during inflammation, include (CRP), (SAA), and fibrinogen. These proteins are transcriptionally upregulated in the liver predominantly by IL-6 signaling through pathways like and . CRP levels can rise dramatically, up to 1000-fold, within hours of an inflammatory stimulus. SAA, another major acute-phase reactant in humans, similarly elevates to modulate immune responses. Fibrinogen synthesis also surges to facilitate and repair processes. Key functions of these proteins enhance innate immunity and limit infection spread. CRP acts as an by binding to on bacterial surfaces, promoting by macrophages and neutrophils while activating the . SAA contributes by opsonizing and influencing macrophage polarization toward phenotypes. Fibrinogen supports clotting to contain tissue damage and forms a provisional matrix that aids endothelial repair and leukocyte migration at injury sites. In contrast, negative acute-phase proteins, such as and , exhibit decreased hepatic production to redirect metabolic resources toward defense mechanisms. levels decline to conserve for synthesizing positive acute-phase proteins, while reduction helps sequester iron from pathogens, contributing to nutritional immunity. These changes reflect a broader metabolic reprogramming in the liver during inflammation. CRP serves as a sensitive for assessing inflammation intensity, with serum levels exceeding 10 mg/L typically signaling an acute response. This threshold distinguishes acute inflammation from baseline states (normal range: <10 mg/L) and aids in monitoring conditions like infections or tissue .

Hematologic Changes

Inflammation induces significant alterations in peripheral populations, primarily through cytokine-mediated signaling that stimulates production and release of leukocytes. In acute inflammation, is a hallmark response, characterized by an elevated count typically exceeding 11,000 cells/μL, predominantly due to as neutrophils are rapidly mobilized to combat or tissue . This neutrophilic predominance reflects the innate immune system's priority in containing acute threats, with cytokines such as interleukin-6 (IL-6) and (G-CSF) driving and demargination of neutrophils from vascular pools. In contrast, chronic inflammation often features , with absolute counts surpassing 4,000 cells/μL, arising from persistent antigenic stimulation that promotes proliferation and recruitment, as seen in conditions like autoimmune diseases or chronic infections. Thrombocytosis, or elevated platelet counts above 450,000/μL, commonly accompanies both acute and chronic inflammation as a reactive process mediated by IL-6 and other proinflammatory cytokines that enhance maturation in the . This increase supports by bolstering the availability of platelets for rapid clot formation at sites of vascular damage or endothelial during inflammatory states, thereby preventing excessive amid heightened tissue repair demands. While beneficial in moderation, extreme thrombocytosis can predispose to thrombotic complications if inflammation persists unchecked. The , also known as anemia of inflammation, develops in prolonged inflammatory states through hepcidin-mediated iron sequestration, where the liver-derived peptide inhibits , the primary iron exporter on macrophages and enterocytes, leading to hypoferremia and restricted iron availability for . Proinflammatory cytokines like IL-6 upregulate hepcidin expression, diverting iron stores into macrophages for nutritional immunity against pathogens while impairing synthesis, resulting in normocytic, normochromic with levels often below 11 g/dL. This mechanism underscores inflammation's role in prioritizing host defense over production. Inflammation also shifts the coagulation system toward a procoagulant state, primarily via upregulated expression of tissue factor (TF) on endothelial cells, monocytes, and vascular smooth muscle cells in response to cytokines such as tumor necrosis factor-alpha (TNF-α) and IL-1. TF initiates the extrinsic coagulation pathway by forming a complex with factor VIIa, accelerating thrombin generation and fibrin deposition to localize hemostasis at inflammatory foci. This interplay between inflammation and coagulation, often termed thromboinflammation, enhances barrier integrity but risks disseminated intravascular coagulation if dysregulated.

Role in Disease

Contribution to Chronic Diseases

Chronic inflammation, characterized by persistent activation of immune responses without effective resolution, plays a pivotal role in the and progression of various non-communicable diseases by promoting tissue damage, , and dysfunction. In these conditions, unresolved inflammatory signals amplify cellular stress, leading to maladaptive remodeling and heightened risk of complications. In , (LDL) oxidation triggers , initiating a cascade of inflammatory events that culminate in plaque formation and instability. Oxidized LDL (oxLDL) binds to scavenger receptors on endothelial cells, upregulating adhesion molecules such as vascular cell adhesion molecule-1 () and intercellular adhesion molecule-1 (), which facilitate recruitment and infiltration into the subendothelial space. These monocytes differentiate into macrophages that engulf oxLDL, forming foam cells and releasing pro-inflammatory cytokines like interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), which perpetuate endothelial injury and cell proliferation. This chronic inflammatory milieu within plaques contributes to their rupture, , and acute cardiovascular events such as . Autoimmune disorders exemplify how dysregulated inflammation drives targeted tissue destruction. In (RA), synovial inflammation leads to hyperplasia of the synovial lining, characterized by proliferation of fibroblast-like synoviocytes and influx of immune cells, forming an invasive that erodes and . Cytokines such as TNF-α and IL-6, produced by activated macrophages and T cells in the synovium, sustain this hyperplasia and angiogenesis, amplifying joint destruction. Similarly, in , autoimmune-mediated inflammation targets pancreatic β-cells, resulting in their progressive destruction through mechanisms involving T-cell infiltration and cytokine-induced . Pro-inflammatory cytokines like interferon-γ (IFN-γ) and IL-1β impair β-cell function and survival, leading to insulin deficiency and . This inflammatory assault, often initiated by viral triggers or genetic susceptibility, culminates in near-complete β-cell loss. Metabolic syndrome involves adipose tissue inflammation as a central driver of insulin resistance, particularly in obesity. Hypertrophic adipocytes in obese individuals secrete chemokines like monocyte chemoattractant protein-1 (MCP-1), recruiting macrophages that polarize toward a pro-inflammatory M1 phenotype and release TNF-α and IL-6. This chronic low-grade inflammation impairs insulin signaling by activating pathways such as c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF-κB), which serine-phosphorylate insulin receptor substrate-1 (IRS-1), reducing glucose uptake in adipose and peripheral tissues. Consequently, systemic insulin resistance ensues, linking adipose inflammation to metabolic dysregulation and increased risk of type 2 diabetes and cardiovascular disease. Neuroinflammation contributes to neurodegeneration in Alzheimer's disease through microglial activation, which exacerbates amyloid-β plaque buildup and pathology. Activated , triggered by amyloid-β aggregates, release pro-inflammatory mediators like IL-1β and TNF-α, promoting a vicious cycle of neuronal injury and tau hyperphosphorylation. Recent highlights how this microglial response, involving TREM2 signaling dysregulation, facilitates tau propagation across brain regions, accelerating cognitive decline. In the , studies have emphasized tau's role in sustaining microglial activation, independent of amyloid, underscoring 's centrality in disease progression.

Inflammation in Cancer and Immunity

Inflammation plays a in cancer, acting both as a promoter of tumor development and as a facilitator of anti-tumor immune responses. Chronic inflammation is recognized as a key enabling characteristic of cancer, often described as the "seventh hallmark" alongside the original six biological capabilities acquired by tumor cells, such as sustaining proliferative signaling and evading growth suppressors. This perspective was updated in subsequent analyses, emphasizing how persistent inflammatory processes contribute to (TME) reprogramming that supports neoplastic progression. In contrast, acute inflammatory responses can enhance immunosurveillance by recruiting and activating immune effectors like natural killer (NK) cells and cytotoxic T cells, which directly target and eliminate nascent tumor cells through mechanisms including perforin-mediated and release. Pro-tumorigenic effects of inflammation are mediated primarily by proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which foster , remodeling, and metastatic dissemination. IL-6, secreted by tumor-associated macrophages and cancer cells, activates the JAK/ pathway in endothelial cells to upregulate (VEGF), thereby promoting neovascularization essential for tumor growth and invasion. Similarly, TNF-α enhances epithelial-to-mesenchymal transition (EMT) in cancer cells, increasing their migratory potential and resistance to , while also recruiting myeloid-derived suppressor cells that dampen adaptive immunity. These cytokine-driven processes exemplify how chronic inflammation sustains a permissive TME, as seen in infections like , where persistent gastric mucosal inflammation induces , DNA damage, and progression to through activation of signaling. Another illustrative case is colitis-associated (CAC), in which leads to repeated cycles of epithelial injury and repair, elevating risk via IL-6-mediated activation and production that drive and invasion. On the protective side, acute inflammation bolsters anti-tumor immunity by initiating the recruitment of NK cells, which recognize stress ligands on transformed cells (e.g., MICA/MICB) and produce interferon-gamma (IFN-γ) to amplify T-cell responses. This coordinated action helps clear immunogenic tumors, particularly when inflammation is triggered by therapies like chemotherapy that expose damage-associated molecular patterns (DAMPs). Recent advances in the 2020s have leveraged this inflammatory-immune axis through PD-1 checkpoint inhibitors, such as pembrolizumab and nivolumab, which reinvigorate exhausted T cells in the TME, enhancing cytotoxic activity against solid tumors like melanoma and non-small cell lung cancer. These immunotherapies harness endogenous inflammatory cues to overcome tumor immune evasion, achieving durable responses in approximately 20-40% of patients across indications, though combination strategies with cytokine modulators are under investigation to mitigate chronic pro-tumor biases.

Resolution and Outcomes

Mechanisms of Resolution

The resolution of inflammation is an active, programmed that actively terminates inflammatory responses and restores tissue , rather than a passive of signals. This phase involves the orchestrated action of (SPMs), cellular clearance mechanisms, and regulatory immune cells to limit leukocyte , promote debris removal, and facilitate repair without . SPMs, including lipoxins derived from the ω-6 polyunsaturated fatty acid (PUFA) and , protectins, and maresins from ω-3 PUFAs such as (EPA) and (DHA), play a central role by countering pro-inflammatory eicosanoids like leukotrienes and prostaglandins. These mediators are biosynthesized via enzymatic pathways involving cyclooxygenases and lipoxygenases during the transition from initiation to resolution phases of inflammation. For instance, A4 inhibits transmigration and stimulates , while (e.g., resolvin D1) and protectins (e.g., protectin D1) reduce production (such as TNF-α and IL-6) and enhance actions without compromising host defense. By binding to specific G-protein-coupled receptors like ALX/FPR2 and GPR32, SPMs promote the "switch" from pro-inflammatory to pro-resolving signals, ensuring timely clearance of exudates and apoptotic cells.00077-6) Efferocytosis, the phagocytic removal of apoptotic cells by macrophages, is a key non-inflammatory clearance mechanism that prevents secondary and the release of damage-associated molecular patterns, thereby dampening further inflammation. Macrophages recognize apoptotic cells through "eat-me" signals like exposed via receptors such as TIM-4 and MerTK, leading to engulfment without triggering pro-inflammatory responses; instead, it induces production (e.g., IL-10, TGF-β) and metabolic reprogramming for tissue repair. This process is essential for resolving acute inflammation, as defects in impair resolution and contribute to persistent inflammation.00527-1) Regulatory T cells (Tregs), particularly + + Tregs, suppress effector T cell and innate immune responses to facilitate resolution, primarily through secretion of immunosuppressive like IL-10 and TGF-β. IL-10 from Tregs inhibits pro-inflammatory release from macrophages and dendritic cells, while TGF-β promotes and by downregulating signaling in effector cells. These actions are context-specific, often at mucosal barriers, and are critical for preventing excessive immune activation during resolution.30335-2) Failure of these resolution mechanisms, such as insufficient SPM production or impaired , can lead to non-resolving inflammation and chronicity, as seen in conditions like where persistent apoptotic cell accumulation drives disease progression. Recent post-2020 research has advanced SPMs toward clinical application; for example, a 2023 demonstrated that SPM-enriched supplementation reduced pain in patients, highlighting potential therapeutic translation for resolving chronic inflammation.

Potential Complications

Prolonged or dysregulated inflammation can lead to and scarring through excessive deposition of components, particularly , in affected tissues. This process often follows unresolved acute inflammatory responses, where persistent activation of fibroblasts and myofibroblasts results in the replacement of normal parenchymal tissue with fibrotic scar tissue, impairing organ function. A prominent example is developing after (ARDS), where initial alveolar injury triggers ongoing inflammation that evolves into widespread lung scarring, reducing gas exchange capacity and leading to chronic . Inflammation can escalate from a localized protective response to systemic autoimmunity, particularly in genetically susceptible individuals, by promoting the breakdown of and the production of autoantibodies. This progression involves chronic immune activation that exposes self-antigens, leading to autoreactive B- and T-cell responses and tissue damage. For instance, initial inflammatory triggers may contribute to the development of systemic lupus erythematosus (SLE), a multisystem autoimmune disorder characterized by widespread inflammation in organs such as the kidneys, , and joints due to immune complex deposition. Overactivation of the inflammatory cascade in response to or can precipitate , defined as a life-threatening caused by a dysregulated host response. This manifests as (SIRS), involving widespread , microvascular leakage, and , which can rapidly progress to and multi-organ failure. Diagnostic criteria for sepsis have evolved, with the Sequential Organ Failure Assessment () score—updated in recent guidelines—used to quantify , where a change of 2 or more points indicates high mortality risk, emphasizing the need for early recognition of inflammatory overdrive. Inflammaging refers to the chronic, low-grade that accumulates with advancing age, driven by and the (SASP), which perpetuates a pro-inflammatory milieu. This state contributes to age-related frailty by exacerbating muscle loss, metabolic dysregulation, and immune exhaustion, increasing vulnerability to infections and comorbidities. Recent studies have expanded on this concept, linking inflammaging to senescent cell accumulation in tissues, which amplifies inflammatory signaling pathways like , thereby accelerating physiological decline in older adults. Chronic inflammation also heightens the risk of cancer by fostering a tumor-promoting microenvironment, though this is explored in detail under inflammation's role in oncology.

Treatment Approaches

Pharmacologic Interventions

Pharmacologic interventions for inflammation primarily target key molecular pathways to suppress excessive immune responses, with classes including corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, and agents for allergic inflammation. These therapies modulate cytokine production, enzyme activity, and cellular signaling to alleviate symptoms and prevent tissue damage in acute and chronic conditions. Selection depends on the inflammatory type, severity, and patient factors, often guided by clinical guidelines from bodies like the American College of Rheumatology. Corticosteroids, particularly such as , exert broad effects by binding to glucocorticoid receptors, which translocate to the nucleus and inhibit pro-inflammatory transcription factors like through induction of inhibitory proteins such as . This mechanism suppresses the expression of multiple inflammatory mediators, including cytokines (e.g., IL-1, IL-6), , and adhesion molecules, providing rapid symptom relief in conditions like and exacerbations. Long-term use requires monitoring for side effects like due to their potent but non-specific suppression. Nonsteroidal anti-inflammatory drugs (NSAIDs), exemplified by ibuprofen, inhibit cyclooxygenase (COX) enzymes—primarily COX-1 and COX-2—to block the conversion of into , key mediators of pain, fever, and inflammation in acute settings such as or post-surgical recovery. By reducing prostaglandin synthesis, NSAIDs decrease and leukocyte recruitment at inflammation sites, though selective COX-2 inhibitors like celecoxib minimize gastrointestinal risks associated with non-selective agents. Biologic therapies target specific cytokines in autoimmune-driven inflammation; anti-tumor necrosis factor (TNF) agents like , a , neutralize soluble and membrane-bound TNF-α, preventing its binding to receptors and downstream activation of inflammatory cascades in diseases such as and . These agents induce in TNF-expressing cells and reduce levels of other cytokines like IL-6 and IL-12, leading to sustained remission in many patients. Recent advancements include IL-23 inhibitors, with approved by the FDA in 2023 for and in 2025 for , selectively blocking the IL-23/IL-17 axis to curb Th17-mediated inflammation without broadly impairing immunity. For allergic inflammation, antihistamines such as diphenhydramine competitively antagonize H1 histamine receptors on endothelial and smooth muscle cells, mitigating vasodilation, bronchoconstriction, and itching in conditions like urticaria or allergic rhinitis. Mast cell stabilizers, including cromolyn sodium, inhibit calcium influx into mast cells to prevent degranulation and release of histamine, leukotrienes, and other mediators, offering prophylactic benefits in asthma and conjunctivitis by stabilizing cell membranes during allergen exposure.

Non-Pharmacologic Strategies

Non-pharmacologic strategies for managing inflammation emphasize lifestyle modifications that target underlying contributors such as , immune dysregulation, and metabolic factors, often yielding reductions in circulating inflammatory markers like (CRP) and interleukin-6 (IL-6). These approaches are supported by clinical evidence showing benefits in preventing or alleviating chronic low-grade inflammation associated with conditions like and . Dietary interventions form a , with anti-inflammatory diets promoting whole, plant-based foods rich in polyphenols, , and omega-3 s while limiting processed sugars and trans fats. The , characterized by high intake of fruits, vegetables, whole grains, nuts, legumes, and fatty fish, has been shown to reduce CRP levels by up to 20% and lower cardiovascular event risk by 30% in high-risk populations. Similarly, the , emphasizing fruits, vegetables, low-fat dairy, and reduced sodium, decreases inflammatory biomarkers and supports control, thereby mitigating vascular inflammation. High- plant-based diets enhance diversity, increasing short-chain production that suppresses pro-inflammatory pathways. Regular , including aerobic and resistance training, induces effects by modulating production and improving insulin sensitivity. Moderate-intensity exercise, such as brisk walking for 30 minutes daily, reduces markers like IL-6 and tumor factor-alpha (TNF-α) in older adults and those with , with meta-analyses confirming a 10-15% decrease in CRP after consistent training. Resistance training further lowers low-grade inflammation linked to and , though excessive high-intensity exercise may transiently elevate markers, underscoring the importance of moderation. Combining exercise with dietary changes amplifies benefits, as seen in interventions where programs reduced inflammation more effectively than diet or exercise alone. Adequate sleep duration and quality are essential, as chronic elevates pro-inflammatory cytokines including IL-6 and CRP, contributing to heightened immune activation. Adults achieving 7-9 hours of restorative sleep nightly exhibit lower inflammation levels, with experimental studies demonstrating that even partial sleep restriction increases inflammatory responses within days. Interventions improving , such as consistent bedtime routines, have been linked to reduced CRP in populations with , highlighting sleep's role in immune . Stress management techniques, including mindfulness meditation, , and deep breathing, counteract the pro-inflammatory effects of chronic , which activates the hypothalamic-pituitary-adrenal axis and elevates and cytokines. Mind-body practices like reduce TNF-α and IL-6 by 10-20% in randomized trials, particularly in individuals with chronic inflammatory conditions, by enhancing parasympathetic activity and resilience. These interventions also improve overall adherence to other changes, fostering sustained inflammation control. Weight management through caloric restriction and sustained lifestyle changes directly addresses adipocyte-driven inflammation, as visceral fat accumulation promotes release. Intentional of 5-10% body weight via diet and exercise decreases CRP by 20-30% and improves inflammation in obese individuals, with showing even greater reductions in systemic markers. This strategy is particularly impactful in metabolic disorders, where it interrupts the cycle of inflammation and .

References

Add your contribution
Related Hubs
User Avatar
No comments yet.